Selected Grants
CISA 2023 Clinical Contributing Task 2
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028CISA 2023 Clinical Contributing Task 1
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028U2C/TL1 NC KUH TRIO Networking Development Core
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028U2C/TL1 NC KUH TRIO Administrative Core
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028U2C/TL1 NC KUH TRIO Professional Development Core
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028Daratumumab in primary APS
Clinical TrialPrincipal Investigator · Awarded by Benaroya Research Institute at Virginia Mason · 2023 - 2028TAK-755-2001 A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2023 - 2026Integrated Training in Anesthesiology Research
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1996 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026Neurocognition & Greater Maintenance of Sinus Rhythm in AF (NOGGIN AF)
Clinical TrialCo Investigator · Awarded by National Institute on Aging · 2021 - 2026The Role of RBC Reactive Oxygen Species in Regulating Thrombotic Events During Aging
ResearchCollaborator · Awarded by National Institutes of Health · 2021 - 2026Anthos ANT-008
Clinical TrialPrincipal Investigator · Awarded by Anthos Therapeutics, Inc · 2022 - 2026Anthos ANT-007
Clinical TrialPrincipal Investigator · Awarded by Anthos Therapeutics, Inc · 2022 - 2026A RANDOMIZED, DOUBLE-BLIND, PHASE 2 PILOT STUDY OF VLX-1005 VERSUS PLACEBO IN PARTICIPANTS WITH SUSPECTED HEPARIN INDUCED THROMBOCYTOPENIA TREATED WITH BACKGROUND STANDARD OF CARE
Clinical TrialPrincipal Investigator · Awarded by Veralox Therapeutics · 2023 - 2025(Takeda cTTP-2) A Phase 3b, open-label, continuation study of prophylactic and on-demand treatment of cTTP with TAK-755 (rADAMTS-13, also known as BAX 930/SHP655)
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2022 - 2025Validation of the clinical performance of HemosIL CL HIT-IgG (PF4-H) on the ACL TOP 970 CL: A Method Comparison Study
ResearchPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2023 - 2025Developing apheresis-specific outcomes to facilitate a multi-center study of therapeutic plasma exchange in heparin-induced thrombocytopenia
ResearchMentor · Awarded by Robert Wood Johnson Foundation · 2020 - 2024IL APS Fresh vs Frozen Clinical Agreement
ResearchPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2018 - 2024Validation of the clinical performance of HemosIL CL HIT-IgG (PF4-H) on the ACL TOP 970 CL Matrix Comparison: Fresh v. Frozen
Clinical TrialPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2024 - 2024Phase 3, prospective, randomized, controlled study of prophylatic and on-demand treatment of cTTP with BAX930 (rADAMTS13)
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2019 - 2024ACTIV IV COVID-19 Post-hospital Thrombosis Prevention Study
Clinical TrialPrincipal Investigator · Awarded by Research Triangle Institute International · 2020 - 2024Phase II, of oral SKI-O-703 in Chronic Immune Thrombocytopenia (ITP)
Clinical TrialPrincipal Investigator · Awarded by Oscotec, Inc. · 2019 - 2023IL ASP Clinical Outcome Study Agreement
ResearchPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2018 - 2023CISA Consult 2022 Contributing Task 3
Clinical TrialInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023Role of myeloid KLF2 in antiphospholipid antibody-mediated thrombosis
ResearchPrincipal Investigator · Awarded by Case Western Reserve University · 2018 - 2023Postdoctoral Training in Genomic Medicine Research
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2017 - 2023ThRombosis exelUsion STudy for STA - Liatest D-DiXL (TRUST)
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2018 - 2023Stago themO® CE marking according to IVDR of DDi M reagent
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2022 - 2023HITSOVA Danaporiod vs Argatroban Phase III open-label, randomized trial
Clinical TrialPrincipal Investigator · Awarded by Aspen Global Incorporated · 2019 - 2023A Phase 2, Uncontrolled, Two-stage, Dose-escalations Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical activity of OMS721 in Adults with Thrombotic Microangiopathies
Clinical TrialPrincipal Investigator · Awarded by Omeros · 2014 - 2023ASP002 A Phase 2, multicenter, open-label extension study to evaluate the long-term safety and tolerability of rozanolixizumab in adult study participants with primary antiphospholipid syndrome.
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma · 2021 - 2023A randomized Phase 2 study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of rozanolixizumab relative to placebo in participants with primary antiphospholipid syndrome.
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma SPRL · 2021 - 2022Obizur EU PASS. Prospective and retrospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice.
ResearchPrincipal Investigator · Awarded by Baxalta, Inc. · 2019 - 2022Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)
Clinical TrialPrincipal Investigator · Awarded by Ablynx · 2016 - 2022Improving venous thromboembolism surveillance with natural language processing
ResearchPrincipal Investigator · Awarded by Association of University Centers on Disabilities · 2020 - 2022Stago NeoPTimal 5 mL and 10 mL Multi-Site Precision Study
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2022 - 2022POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A
Clinical TrialPrincipal Investigator · Awarded by Baxalta, Inc. · 2016 - 2022Stago STA® - NeoPTimal 5 and 10 mL Single Site Precision Study
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2022 - 2022PBI - Determination of Reproducibility and Accuracy of CRYOcheck Factor VIII Deficient Plasma with VWF
ResearchPrincipal Investigator · Awarded by Precision BioLogic, Inc · 2022 - 2022Siemans/VWF - Hemosil and REAADS Study
ResearchPrincipal Investigator · Awarded by Siemens Healthcare Diagnostics · 2019 - 2021Stago - STA-NeoPTimal 5ml and 10 ml Single Site Precision Study
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2020 - 2021Stago - STA-NeoPTimal 5ml and 10m: Multisite Precision Study
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2020 - 2021L000013105 Protocol for Reagent Reproducibility of Liquid Anti-Xa Assay with Apixaban Calibrators on ACL TOP Analyzers
ResearchPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2020 - 2021Defining the role of therapeutic plasma exchange in heparin induced thrombocytopenia
ResearchCo-Mentor · Awarded by Hemophilia & Thrombosis Research Society · 2017 - 2020Evaluation, analysis, and dissemination of population-based cancer-associated venous thromboembolism (VTE) data
ResearchPrincipal Investigator · Awarded by Association of University Centers on Disabilities · 2018 - 2020Apixaban for the Secondary prevention of Thromboembolism: a prospective, randomized, outcome pilot study amount patients with AntiphosPholipid Syndrome (ASTRO-APS)
Clinical TrialPrincipal Investigator · Awarded by Intermountain Healthcare · 2019 - 2019L0022511991 Rev 01 Liquid Anti-Xa Assay with Rivaroxaban Calibrators and Controls Performance Evaluation Protocol on ACL TOP
ResearchPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2018 - 2019LOO22511932 Rev 01 Hemosil Direct Thrombin Inhibitor (DTI) Assay with Dabigatran Calibrators and Controls
ResearchPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2018 - 2019L0022511987 Rev 01 Hemosil, Liquid Anti-Xa Assay with Apixaban Calibrators and Controls Performance Evaluation and Fresh vs Frozen Stability Protocol on ACL. TOP 50 Family Series Analyzers
ResearchPrincipal Investigator · Awarded by Instrumentation Laboratory Company · 2018 - 2019A Whole Blood Collection from subjects clinicially diagnosed with PNH
Clinical TrialPrincipal Investigator · Awarded by Discovery Life Sciences, Inc. · 2015 - 2019Duke-UNC Clinical Hematology and Transfusion Research Career Development Program
ResearchAssociate Program Director · Awarded by National Institutes of Health · 2006 - 2019Warfarin versus Direct Oral Anticoagulants for Secondary Prevention of Recurent Venous Thromboembolism
Clinical TrialPrincipal Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2017 - 2019Development of Prognostic Platelet RNA Biomarkers To Tailor Antiplatelet Therapy
ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2019Task Order 1 under Master Eval Agreement #17072705
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2017 - 2018U.S. External Site Protocol for Evaluation of Precision Performances of STA-THROMBIN ON STA-SATELLITE
ResearchPrincipal Investigator · Awarded by Diagnostica Stago · 2017 - 2018External Evaluation of Assay Applications on The Sysmex CS2500 and CS-5100 Analyzer (Wave C)
ResearchPrincipal Investigator · Awarded by Siemens Healthcare Diagnostics · 2016 - 2018A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno- Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B
Clinical TrialPrincipal Investigator · Awarded by Dimension Therapeutics, Inc. · 2016 - 2018Improving Pain in Sickle Cell Patients With Targeted Antithrombotic Therapy
ResearchCo-Mentor · Awarded by National Institutes of Health · 2014 - 2017Training Program in Inflammatory and Immunological Diseases
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1980 - 2017STA - Coag Control ABN PLUS Precision Study
ResearchPrincipal Investigator · Awarded by Stago · 2017 - 2017Evaluation of an Automated Information Extraction Tool for Identification of Venous Thromboembolism in Electronic Health Records (EHRs)
ResearchPrincipal Investigator · Awarded by Association of American Medical Colleges · 2016 - 2017Population-based Surveillance And Ourcomes of Venous Thromboembolism
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2015 - 2017Anticoagulation Withdrawal in Antiphospholipid Syndrome
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2017BRIDGE CCC
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2008 - 2017Siemens CS-2100i and CS-5100 New Generation Analyzers
ResearchPrincipal Investigator · Awarded by Siemens Healthcare Diagnostics · 2015 - 2017Precision Performance of STA® -COAG CONTROL (N + ABN) PLUS ON STA -SATELLITE®
ResearchPrincipal Investigator · Awarded by Stago · 2016 - 2016ALXN1007-APS-201 An Open-label proof of concept Phase IIa trial of ALXN1007 for the treatment of non-criteria manifestations of Antiphospholipid Syndrome
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2014 - 2016Field Study to evaluate the activity of a site specific of B-Domain Deleted (BDD) pegylated recombinant FVIII protein (BAY 94-9027) in plasma samples measured with both chromogenic and one stage assa
ResearchPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2015 - 2016Public Health Surveillance of Bleeding
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2011 - 2016Adherence to Venous Thromboembolism Prophylaxis Guidelines in Hospitalized Elders
ResearchCollaborator · Awarded by National Institutes of Health · 2014 - 2016Promoting the Health of Individuals with Clotting Disorders
Public ServicePrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2013 - 2015Population-based Surveillance And Outcomes of Venous Thromboembolism
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2012 - 201512091912 INR Project
ResearchPrincipal Investigator · Awarded by DSRV Inc · 2013 - 2014Transfusion Medicine/Hemostasis Core Clinical Center
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2007 - 2014Clinical Significance of protamine/heparin antibodies after CPB
ResearchConsultant · Awarded by National Institutes of Health · 2011 - 2014Responses of Myocardial Ischemia to Sertraline Treatment
ResearchCo Investigator · Awarded by National Institutes of Health · 2006 - 2013Thrombosis and Hemostasis Centers Research and Prevention Network
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2002 - 2013Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2009 - 2012Molecular Biology Of Human Coagulation Factor V
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 2012Rare Thrombotic Diseases Clinical Research Network
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2004 - 2010Lung Injury Protection by Coagulation Blockade
ResearchCo Investigator · Awarded by National Institutes of Health · 2005 - 2010Pharmacologic Prevention of Arteriovenous Graft Thrombosis
ResearchMentor · Awarded by National Institutes of Health · 2007 - 2009Biomarker Studies for Novel Anti-Cancer Agents
ResearchConsultant · Awarded by National Institutes of Health · 2003 - 2008Hormone replacement therapy and ischemic stroke severity
ResearchCollaborator · Awarded by National Institutes of Health · 2001 - 2007Integrated Program for Persons with Hemostatic Disorders
ResearchPrincipal Investigator · Awarded by Centers for Disease Control · 2001 - 2007Mentored Clinical Research Scholar Program
ResearchMentor · Awarded by National Institutes of Health · 2002 - 2006Does NO mediate clinical anti-VEGF vascular effects
ResearchConsultant · Awarded by National Institutes of Health · 2003 - 2006Genetic Analysis of Hereditary Macrothrombocytopenias
ResearchCo Investigator · Awarded by National Institutes of Health · 2001 - 2004Same
ResearchPrincipal Investigator · Awarded by Department of Health and Human Services · 1999 - 2004External Relationships
- Dade Behring, Inc. (Siemens)
- Diagnostica Stago
- Instrumentation Laboratory
- Sanofi
- The American Society of Hematology (ASH)
- Up To Date Inc/Wolters Kluwer Health
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.